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In vivo dosimetry (IVD) has been used in brachytherapy (BT) for decades with a number of different
detectors and measurement technologies. However, IVD in BT has been subject to certain difficulties
and complexities, in particular due to challenges of the high-gradient BT dose distribution and the
large range of dose and dose rate. Due to these challenges, the sensitivity and specificity toward error
detection has been limited, and IVD has mainly been restricted to detection of gross errors. Given
these factors, routine use of IVD is currently limited in many departments. Although the impact of
potential errors may be detrimental since treatments are typically administered in large fractions and
with high-gradient-dose-distributions, BT is usually delivered without independent verification of the
treatment delivery. This Vision 20/20 paper encourages improvements within BT safety by devel-
opments of IVD into an effective method of independent treatment verification. © 2013 American
Association of Physicists in Medicine. [http://dx.doi.org/10.1118/1.4810943]
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I. INTRODUCTION
In vivo dosimetry (IVD) has been used in brachytherapy
(BT) for decades and has been referred to in International
Commission on Radiation Units and Measurements (ICRU)
recommendations.1 The initial motivation for performing
IVD in BT was mainly to assess doses to organs at risk (OAR)
by direct measurements, because precise evaluation of OAR
doses was difficult without 3D dose treatment planning. With
the introduction of 3D image-guided BT, it is now possible to
calculate 3D tumor and OAR doses as well as dose volume
histogram (DVH) parameters by the treatment planning sys-
tem (TPS).2–4 Recording and reporting of dose based on 3D
images is an important step forward. Current 3D image-based
dose calculations are often more accurate for assessments of
OAR doses than IVD measurements. However, there are sit-
uations with significant dose calculation uncertainties, in par-
ticular for low-energy photon-emitting sources and in hetero-
geneous media, where IVD may contribute to more precise
dose reporting.5 Furthermore, potential organ movement in
between imaging and treatment contributes to uncertainties in
delivered dose, and IVD may have a potential role for identi-
fication of organ or applicator movements.
The complexity of BT has increased with the introduction
of remote afterloading and 3D image-based dose planning.
However, independent and patient specific quality assurance
(QA) of dose delivery is not performed systematically, despite
the risk of errors during the many manual steps involved in
treatment planning and delivery. Furthermore, BT is typically
administered with large doses per fraction (>5 Gy), which
means that the consequence of a fractional error may be sub-
stantial when compared to typical external-beam radiother-
apy (EBRT) with delivery of smaller doses per fraction (e.g.,
2 Gy). From this perspective, IVD is very relevant in BT as
an independent method for detection of deviations or errors.6
Unfortunately, the interest has suffered much from difficul-
ties and uncertainties of dose measurement, in particular the
challenges of precise detector positioning in the high dose
gradient fields. Error detection sensitivity and specificity of
current systems has been compromised by such uncertainties,
and therefore it seems that current IVD is only able to detect
gross errors (Sec. IV.C), which happen less frequently. Fur-
thermore, there has been a lack of good infrastructure in terms
of commercially available dosimetry systems with straightfor-
ward procedures, which do not require extensive manpower
and expertise. Substantial progress is needed in dose measure-
ment methodology and infrastructure in order to bring IVD to
its full potential.
Whereas IVD in BT needs further development to become
well integrated into routine clinical practice, the situation is
different in EBRT where IVD is more widely used and ac-
cepted as an independent check of dose delivery.7, 8 Confor-
mal EBRT is characterized by flat dose profiles and homoge-
neous dose in the target region. Therefore, conformal EBRT
IVD for target dose verification has not suffered from the par-
ticular challenge typical for BT, which is detector positioning
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in high gradient fields. However, due to the heterogeneous flu-
ence profiles and dose gradients,9 IVD in IMRT and VMAT
for dose assessments in OARs, for instance, would involve
some of the same challenges as are seen with BT. The energy
dependence of detectors is often more crucial in BT as com-
pared to EBRT because of the lower photon energy applied
in BT. However, most small detectors that are used for IVD
in EBRT,7 are in principle also suitable in BT. Transmission
IVD based on, e.g., EPID has much potential for EBRT,10 but
has not yet been much exploited for BT. In the accompanying
Vision 20/20 paper,11 the current and future justifications of
performing external beam IVD are discussed, and a compre-
hensive review of detectors used for IVD is provided.
The purpose of the current Vision 20/20 paper is to discuss
current and future justifications of IVD for BT, and to iden-
tify current challenges that need to be addressed in order to
advance the field over the next decade.
II. JUSTIFICATION FOR IN VIVO DOSIMETRY
II.A. Errors and treatment variations in brachytherapy
There is currently no systematic overview of the type and
frequency of errors which occur in BT. Existing reports of BT
accidents and errors are mainly based on retrospective event
collection since prospectively structured investigations have
not yet been performed on a multicenter scale. Furthermore,
since current IVD systems suffer from unknown or poor sen-
sitivity and/or specificity (see below), there are an unknown
number of BT errors that remain undetected.
The International Commission on Radiological Protection
(ICRP) Report Nos. 86 (Ref. 12) and 97 (Ref. 13) as well as
IAEA safety report series 17 (Ref. 14) describe errors that
have occurred in BT. BT errors and accidents are mainly
related to human errors, although some errors are caused
by mechanical events related to malfunction of the equip-
ment. Examples of human errors are incorrect medical indi-
cation, source strength, patient identification, diagnosis or site
of treatment, prescription, data entry, catheter, or applicator.
High dose-rate (HDR) and pulsed dose-rate (PDR) afterload-
ing techniques may introduce source positioning errors which
are related to procedures specific for afterloading dose plan-
ning and treatment delivery. Source positioning errors may
also occur in low dose-rate (LDR) manual loading procedures
due to manual misplacement or source migration after the
placement.
Afterloading BT embraces a variety of approaches to treat-
ment planning, each involving specific error scenarios. Treat-
ment planning can be performed without the use of a TPS
by directly defining the target from x-ray image or clinical
findings and applying a standardized or manually optimized
treatment plan. An example would be an esophagus treat-
ment where the treatment length, source offset, step size, and
dwell times may be directly defined on site in some clinics
and followed by a more or less manual entry of treatment pa-
rameters into the afterloader control software. For this sce-
nario, the risk of errors is mainly related to the definition and
manual entry of parameters. A number of manual steps are
avoided with 3D image-based treatment planning. However,
other sources of potential errors are introduced in this pro-
cedure. With 3D image-based dose planning, both target and
source catheters are defined with imaging modalities such as
ultrasound (US), magnetic resonance imaging (MRI), or com-
puted tomography (CT). Mistakes or uncertainties in identifi-
cation of source catheters or definition of applicator length
can lead to source positioning errors. Dose optimization may
involve a high degree of dwell time modulation, which means
that the consequence of source positioning errors can lead to
significant errors throughout the volumetric dose distribution.
The treatment plan is usually directly exported from the treat-
ment planning system to the treatment control station (TCS)
and the afterloader. The automatic transfer reduces the risk of
incorrectly entered parameters, although there is still a risk
that a wrong plan is exported or imported. After treatment
plan transfer, the afterloader is connected to the applicators;
this process involves a risk of misconnection of the source
transfer guide tubes.
Organ or applicator movement in between imaging and
treatment represents a limitation on the accuracy of dose de-
livery unless imaging is performed immediately before deliv-
ery in a BT suite. For prostate BT, there have been reports
of needle movements,15, 16 and for gynecological BT, organ
movement has been seen as well as occasional relocation of
the applicator.17 IVD may be a tool for detection of such dis-
placements and movements. However, direct inspection of the
applicator (e.g., measurement of free needle length in prostate
BT) or reimaging directly before treatment delivery may be an
alternative way to validate that the dose delivery and dose
recording are appropriate.18 Neither the use of repeated imag-
ing nor IVD has demonstrated wide practical application for
detection of organ and applicator movement. The conditions
under which each of these may be practical and/or precise
enough for use in clinical practice still remain to be clarified.
Certain errors can be identified by the afterloader safety
systems which include builtin dummy check sources, a radi-
ation detector, and source cable length control.19 However,
afterloader safety systems are only able to detect a subset of
all possible errors that may occur. Additional manual safety
checks of the treatment planning and delivery procedure may
be introduced such as verification of applicator reconstruc-
tion or source guide tube connection by a second observer.
In addition, as documented in ICRP and IAEA reports,12–14
there are a number of errors that are not detected by safety
systems or manual checks. IVD has the potential to comple-
ment other QA and quality control (QC) procedures, as part
of the greater process of quality management, by providing
an independent overall verification of the treatment delivery
(Table I).
II.B. Recording of dose in individual patients
The increasing use of image-guided BT has been a huge
step forward for the calculation and recording of tumor and
OAR doses. In most cases, dose calculation is more accurate
than IVD, mainly due to the challenge of precise detector po-
sitioning to measure the specific OAR or tumor doses (see,
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TABLE I. QA and detection of errors and variations occurring with afterloading BT.
Quality item Typical quality test Role of in vivo dosimetry
Source calibration Independent source calibration in the department Minor importance, but may in certain situations
reveal calibration errors (if the in vivo dosimeter
calibration is independent from the actual
source).
Afterloader source positioning and dwell time
(nonpatient specific)
Autoradiography, commissioning of applicators,
other source stepping and dwell time QA
Minor importance, but may in certain situations
reveal errors which have not been identified with
standard nonpatient specific QA.
Afterloader malfunction Unpredictable afterloader malfunction is
difficult to target with general QA.
Major relevance, since afterloader malfunction
may have significant impact on dose, and IVD
has good potential to reveal such errors.
Patient identification Manual check Not relevant
Correct treatment plan Manual check Relevant since it may detect if a wrong plan is
used for treatment, if DICOM transports to the
afterloader and dosimeter software are
independent.
Intra- and interfraction organ/applicator
movement
Reimaging performed just before treatment
delivery can in some cases be used to assess
organ or tumor dose in image-guided BT.
The relevance depends on detector positioning.
If the detector is fixed to the applicator, it will
not reveal applicator movement, contrary to
measurements in, e.g., urethra. For the organ
dose change detection, there are significant
challenges to position the detector precisely
(reimaging may be preferred).
Applicator reconstruction and fusion errors Manual check Relevant. Can detect applicator reconstruction
errors when the dosimeter is placed in an
optimal geometry.
Applicator length/source-indexer length Manual check Major relevance, since “source-indexer length”
errors may have significant impact on dose, and
real time IVD has good potential to reveal such
errors.
Source step size (patient specific) Manual check Major relevance if source step size is entered
manually. Otherwise the appropriate method to
check source stepping is part of nonpatient
specific QA.
Interchanged guide tubes Manual check Major relevance, since interchanged guide tubes
may have significant impact on dose, and IVD
has good potential to reveal such errors.
Recording of dose General QA related to dose calculation in the
TPS
Relevant when dose recording is not calculated
with sufficient accuracy by 3D image based TPS
calculation (e.g., lack of inhomogeneity or
radiation scatter corrections).
e.g., Sec. IV.C). However, for certain clinical situations TPS
based dose calculations are currently associated with system-
atic deviations due to lack of corrections for heterogeneities
and scatter conditions.20 This is particularly true for low en-
ergy sources such as 125I or 103Pd used in permanent implants
of prostate, lung, and recently breast.21–23
Some dosimetry systems define specific points or volumes
for dose reporting for individual patients such as the Paris
System for interstitial implants;24 ICRU 38,1 GEC European
Society for Radiotherapy and Oncology (ESTRO),2 and ABS
for cervix BT;25, 26 as well as ABS (Ref. 27) and GEC ESTRO
(Refs. 28 and 29) for prostate implants. This kind of report-
ing is important in treatment outcome assessments. However,
the reporting is mostly based on treatment planning identi-
fication of such points/volumes. In the situation where the
tumor and OARs move and/or get deformed, as is the case
during permanent prostate implants, IVD can provide ad-
ditional information about the dose delivered to the tumor
and/or OAR for the given patient. In particular, for LDR and
PDR treatments that involve long irradiation times, there may
be anatomical changes such as prostate swelling, applicator
movement, and organ movement, and IVD may be used to
monitor the treatment progression. There have been studies
of the point or segment dose measurements in rectum or ure-
thra for gynecological30, 31 or prostate implants32–34 or in the
tumor.35, 36 Some results confirm the agreement between the
calculated and delivered doses, while others point to discrep-
ancies between them. The reasons for these disagreements
are not always clear and underscore the technical difficulties
faced by IVD in BT.
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III. CURRENT CLINICAL PRACTICE
Typical sites for IVD are rectum,37–40 and bladder or
urethra.32, 33, 41 Noninvasive detector positioning far from the
source, e.g., on the skin, make the measurements insensitive
to error detection because of low signal and difficulties to
know precisely the relation between the source(s) and detec-
tor(s). IVD on skin is of relevance during the treatment of
breast cancer42–44 since the skin is an OAR close to the treated
volume and has significant dose calculation uncertainties.45
The practice of using IVD varies considerably among
countries. In most countries, systematic use of IVD is not of-
ten incorporated as a standard QA or QC procedure. How-
ever, there is specific legislation in a number of countries
making IVD obligatory. For example, France recently intro-
duced a law that requires some form of IVD be performed on
all EBRT patients.46 Unfortunately, there are no reports avail-
able about the value and benefit of routine BT IVD in these
countries. In patterns-of-care studies from Europe and Latin
America, it has been difficult to collect responses that homo-
geneously represent all countries.47, 48 However, it seems that
IVD is available in many institutions because it is reported
to be used by 20%–33% of the centers.47–49 However, it is
not further described how often, in which disease sites, or in
how many patients. A recent survey by Sawakuchi et al.103
on Canadian cancer clinics showed that most of the clinics
perform some form of IVD for special EBRT techniques.
However, no IVD is performed routinely for BT treatments
in Canada. A Japanese patterns-of-care study of cervix can-
cer reports that rectal and bladder IVD was used in 27% and
3% of the BT patients, respectively.50 IVD was carried out in
1.2% U.S. centers that performed vaginal BT in endometrial
cancer patients.51 From available literature and institutional
reports, it seems that IVD most often appears as diode rectal
dosimetry performed during intracavitary BT in gynecolog-
ical cancer. There are a number of groups reporting institu-
tional use of IVD in prostate cancer, but there are no general
reviews or reports that indicate this technique is commonly
used, or what was the observed error rate.
IV. CHALLENGES SPECIFIC TO IN VIVO
DOSIMETRY IN BRACHYTHERAPY
IV.A. High dose gradients and detector positioning
The BT dose distributions are characterized by steep dose
gradients that depend strongly on the distance from the detec-
tor to the source. At a distance of 4 mm from a linear source,
the dose gradient is approximately 50%/mm. The gradient de-
creases to around 6%/mm and 5%/mm at distances of 20 and
35 mm, respectively. Therefore, even small uncertainties in
detector positioning may lead to significant uncertainties in
dose measurements. The ability of IVD to detect errors de-
pends critically on where the detectors can be placed and how
well these detector positions are known. The optimal region
for detector placement balances the favorable signal-to-noise
ratio (SNR) with the smallest possible impact of positional
uncertainties.35, 36 This optimal region is different and specific
for each detector and patient category due to differences in
positional uncertainties of the detector as well as sensitivity,
energy dependence, and angular dependence of the detector
response.
The steep dose gradient induces additional challenges
when IVD is used for individual measurement of organ dose.
The dosimeter needs to be positioned in a clinically relevant
region, and for the bladder and rectum, it is a major difficulty
to establish a stable dosimeter position directly adjacent to
the most exposed part of the organ wall.52 The anatomy of
the urethra is more favorable for performing accurate IVD in
prostate BT since this organ is smaller and less deformable.
Several challenges regarding optimal dosimeter positioning
could be solved with dedicated clinical components, e.g., ure-
thral catheters and rectal or bladder balloons, that would both
stabilize and offer accessibility at desired dosimetry sites (see
Sec. VI.A).
Ease of positioning as well as good detector stability can
be obtained by insertion of extra invasive catheters or needles.
However, the potential use of such invasive procedures raises
ethical issues because of accompanying risks for the patient
such as infection. The extra procedure must be of clear ben-
efit to the patient and since IVD still has to demonstrate that
it adds significant improvement in terms of safety and qual-
ity there is currently reluctance among clinicians to introduce
extra invasive procedures.
IV.B. Energy dependence of detectors
Another major challenge for IVD in BT is the energy de-
pendence (relative absorber dose sensitivity) (Ref. 53) of ex-
isting detectors in the intermediate-to-the-low energy range of
the photon or gamma energy spectra that are commonly en-
countered (60Co, 137Cs down to 103Pd) covering >1 to <0.03
MeV photons.54 The energy dependence of a detector is de-
fined as the dependence of the detector reading as a function
of the absorbed dose in water on the photon or electron energy
spectrum. Energy dependence has implications both for cali-
bration of the dosimeter and for conversion of detector read-
ing into measured dose during patient measurements. Most
commonly used detectors exhibit a higher energy-dependence
in BT than in megavoltage beams, because the photoelec-
tric effect causes an over-response in the BT energy range.
This is due to the fact that detector response depends more
on the mass-attenuation absorption coefficients (large cavi-
ties) than on the mass-collisional stopping powers (small cav-
ities: satisfying the Bragg-Gray conditions). Therefore, the
energy dependence (absorbed dose sensitivity) needs to be
determined for the type of detector used for the specific ra-
dioactive source since the energy spectrum depends also on
source model (especially for low-energy sources). The ab-
sorbed dose sensitivity must be corrected for if the source
is calibrated with a radiation source different from the BT
source. Even more challenging is that the detector response
may change with depth in tissue from the source because the
BT photon energy spectrum changes as function of source
distance.
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TABLE II. Treatment error detection and definition of specificity and sensitivity.
Correctly delivered treatment Error in treatment delivery
No alarm (negative test): Measurements do not True negative (correctly no alarm) False negative.
indicate any inconsistency with expected dose Type II errors (failure to detect a treatment error)
Alarm (positive test): Measurements indicate False positive. True positive (correct alarm)
inconsistency with expected dose Type I errors (false alarm)
↓ ↓
Specificity Sensitivity
∑
True negative∑
Condition negative
∑
True positive∑
Condition positive
IV.C. Sensitivity and specificity
Sensitivity and specificity are statistical measures of the
performance of a binary test such as the classification
of an in vivo measurement into “No alarm” or “Alarm”
(Table II). The sensitivity measures the proportion of actual
positives which are correctly identified as such (e.g., the per-
cent of treatment errors which are correctly identified as er-
rors). Specificity measures the proportion of negatives which
are correctly identified (e.g., the percentage of correct treat-
ments which are correctly identified as not being affected by
errors). These two measures are closely related to the concepts
of type I (false alarm) and type II (lack of error detection) er-
rors. Type I and II errors are statistical concepts and should
not be mixed up with “treatment error.” For instance, a type
I error would indicate an alarm during a correctly adminis-
tered treatment, hence indicating “false alarm.” A theoretical,
optimal system aims to achieve 100% sensitivity (i.e., iden-
tify all errors) and 100% specificity (i.e., not induce any false
alarms). For any system, there is a trade-off between sensi-
tivity and specificity since the number of false alarms is in-
creased if the sensitivity is increased by lowering the thresh-
old for error detection.
An inherent problem of current IVD systems is poor sen-
sitivity and specificity. A typical example of standard rectal
IVD performed during intracavitary BT for cervical cancer
is shown in Fig. 1. Figure 1 shows the measured accumulated
diode dose per BT fraction compared with the calculated dose
from the treatment planning system based on MR images.
The discrepancy between measured and calculated doses was
−9% ± 18% [mean and standard deviation (SD)]. There is
a significant variation in the difference between calculated
and measured doses, and discrepancies larger than 30% oc-
curred in 10% of the treatment fractions. Numerous reports
show examples of the same magnitude of deviations in clin-
ical measurements,40, 55–57 and notably such a measurement
approach is likely to detect only gross errors >50%.
In order to avoid false alarms, current error decision cri-
teria are usually high, which means that the error detection
sensitivity is low. Currently, flat error criteria are mainly used
in clinical practice. However, a flat criterion of, e.g., 10% may
result in false alarms when the detector is close to the source,
where positional uncertainties of the detector lead to dose un-
certainties larger than 10%.36 On the other hand, 10% may
be too large for treatment error detection at larger source-
detector distances where the influence of positional uncertain-
ties is less.36
V. DETECTORS: STATE OF THE ART
Many dose-measurement systems have been used in BT
in spite of the practical challenges encountered or the
FIG. 1. Rectal IVD in PDR 192Ir cervix cancer BT with tandem ring applicator for BT fractions 1 (BT1) and 2 (BT2). Dashed lines indicate bounds of the 95%
prediction interval.
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TABLE III. Characteristics of detectors and dosimetry systems of importance for precise routine IVD in brachytherapy. The items are rated according to:
advantageous (++), good (+), and inconvenient (−).
TLD Diode MOSFET Alanine RL PSD
Size + +/− +/++ − ++ ++
Sensitivity + ++ + − ++ +/++
Energy dependence + − − + − ++
Angular dependence ++ − + + ++ ++
Dynamic range ++ ++ + − ++ ++
Calibration
procedures, QA,
stability, robustness,
size of system, ease
of operation
+ ++ ++ − −/+ +/++
Commercial
availability
++ ++ ++ ++ − +
Online dosimetry − ++ + − ++ ++
Main advantages No cables, well
studied system
Commercial
systems at
reasonable price,
well studied system
Small size,
commercial system
at reasonable price
Limited energy
dependence, no
cables
Small size, high
sensitivity
Small size, no
angular and energy
dependence,
sensitivity
Main disadvantages Tedious procedures
for calibration and
readout, not online
dosimetry
Angular and energy
dependence
Limited life of
detectors, energy
dependence
Not sensitive to low
doses, tedious
procedures for
calibration and
readout, not online
dosimetry,
expensive readout
equipment not
available in clinics
Needs frequent
recalibration, stem
effect, not
commercially
available
Stem effect
shortcomings in their physical properties such as en-
ergy response, signal noise ratio, signal stability, read-
out precision, and positional accuracy.54 In principle, de-
tectors that are commonly used for the EBRT absorbed
dose measurements may be good candidates for appli-
cation for IVD for BT. Few studies have been con-
ducted in the past to compare the performance of these
detectors for both high dose BT and EBRT.58–60 Ther-
moluminescent dosimeters (TLD),32, 42, 61–63 semiconductor
diodes,30, 64 metal-oxide-semiconductor field-effect transis-
tors (MOSFET),33, 34, 65 radioluminescence (RL) and optically
stimulated luminescence (OSL) detectors,66 plastic scintil-
lation detectors (PSD),41, 67–70 alanine detectors,39, 71 radio-
photoluminescent glass dosimeters (RPLGD) (Refs. 55, 56,
and 72) have been used for IVD in BT to measure doses
over an assortment of disease sites. The characteristics and
the operation of these detectors are briefly described below,
and have also been presented and discussed in the accompa-
nying Vision 20/20 paper for EBRT,11 in review papers,73 as
well as in textbooks.74, 75
There is no ideal detector for all BT measurements be-
cause of the severe requirements needed and demands ex-
pected of the dosimeters. All currently used detectors exhibit
varying degrees of artifacts such as volume-averaging, self-
attenuation, response angular anisotropy, energy dependence,
and a nonlinear dose response. Therefore, BT detector se-
lection is crucial and is dictated by the radioactive source in
question, the spatial locations of the measurement points with
respect to the source, practical insertion(s) of the detectors,
and the disease site. Only detector designs that can be easily
inserted within either intraluminal catheters or special appli-
cators inserted into patients should be considered. Table III
presents an overview of characteristics of the most relevant
detectors for IVD in BT and an evaluation of their advantages
and disadvantages.
V.A. TLDs and RPLGDs
TLDs have been used for HDR 192Ir BT to measure the
dose to the urethra and/or rectum during prostate treatments
(24–28). TLDs come in a variety of materials and forms and
can be shaped to easily fit into various areas of interest. The
lithium fluoride (LiF) TLD rods are the most widely used
form, because they can be easily inserted into catheters. How-
ever, they require special preparation (annealing, individual
calibration, careful handling, fading correction, etc.) and do
not provide a direct reading right after the treatment. The
combination of these properties places them into a secondary
choice compared to other dosimetry systems that are capable
of providing reading in real time.
RPLGDs have a similar reading process to TLDs, except
ultraviolet light (and not heat) is used to stimulate the detec-
tor. Irradiation of the silver-activated phosphate glass converts
silver ions to stable luminescent centers; when exposed to ul-
traviolet light, the luminescent centers produce fluorescence
in proportion to the absorbed radiation dose. These detectors
Medical Physics, Vol. 40, No. 7, July 2013
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have been used for IVD (42–44) by Nose et al.55, 56 for
HDR interstitial BT for head-and-neck cancer (61 patients)
and pelvic malignancies (66 patients). In the case of the pelvic
patients, the RPLGDs were sutured to the anterior wall of the
rectum or positioned inside a Foley catheter inside the ure-
thra. Deviations greater than 20% were found between the
measured and calculated doses and were attributed to the in-
dependent movement of the organs and applicators between
the planning and treatment delivery times.
V.B. Semiconductor diodes
Diodes are another type of semiconductor solid-state
dosimeters, typically based on silicon. They are mostly used
for EBRT but have been also employed for in vivo verifica-
tion of BT plans. They have the advantage of providing users
with an immediate readout, high sensitivity, good mechan-
ical stability, fairly small size. Unfortunately, they are also
known for the undesirable dosimetric characteristics which
include directional dependence, energy dependence, temper-
ature dependence, and changes in sensitivity due to radiation
damage. As these characteristics affect the accuracy of the
dosimetry system, they must be thoroughly characterized in
phantom before clinical use for the specific radiation source
or application.57, 76
Waldhäusl et al.64 and Seymour et al.57 both used flexible
diode array manufactured by PTW for IVD for patients un-
dergoing HDR 192Ir treatments. Waldhäusl et al.64 evaluated
suitability of rectal probes consisting of five diodes (separated
by 15 mm) and bladder probes consisting of a single diode for
IVD of cervix cancer patients. Their measurements resulted in
differences between calculated and measured doses ranging
from −31% to +90% (mean 11%) for the rectum and from
−27% to +26% (mean 4%) for the bladder. They also re-
ported that shifts in probe position of 2.5 mm for the rectal
probe and 3.5 mm for the bladder probe caused dose differ-
ences exceeding 10%. Seymour et al.57 performed a dosimet-
ric evaluation of the five diode array in the routine verifica-
tion of planned dose inside the rectum for prostate (HDR) BT
using a real-time planning system. The deviations between
the diode measurements and the TPS predicted values ranged
from −42% to +35% (with 71% of the measurements within
10% of the predicted values). Waldhäusl et al.64 and Sey-
mour et al.57 estimated that the overall uncertainty involved in
phantom dose measurement, after correcting for all the factors
affecting diode response were ±7% (SD) and ±10% (SD),
respectively.
V.C. MOSFET detectors
MOSFETs are miniature n- or p-type silicon (Si) semicon-
ductors. For dosimetry, mostly p-type detectors are used. In
general, MOSFETs as all semiconductors, exhibit tempera-
ture dependence. However, this effect has been overcome by
specially designed dual-MOSFET-dual bias detectors77 pro-
duced by Best Medical Canada. These detectors can be pro-
duced either in standard size, or as micro-MOSFETs. The lat-
ter ones are particularly suitable for BT due to their small
size (8 × 2.5 × 1.3 and 0.2 × 0.2 × 5 × 10−4 mm3 for ex-
ternal and sensitive volume dimensions, respectively). They
are also available in the form of an array of five detectors.
Micro-MOSFETs have almost isotropic response to radiation.
Unlike single dual-MOSFET-dual bias detectors, MOSFET
arrays have some temperature dependence (the temperature
coefficient = 0.6%/◦C).34 Most published studies on IVD in
BT involve detectors and dosimetry system from Best Med-
ical Canada. Another MOSFET dosimetry system used in
BT comes from the Centre for Medical Radiation Physics
(CMRP), University of Wollongong.78 It was found that their
response degrades with exposure to radiation and varies with
distance from a source due to its dose rate and energy depen-
dence. MOSFET system from CMRP is not yet available in
the market.
The two main disadvantages of MOSFETs for BT mea-
surements are: (1) they are not tissue equivalent, which makes
their dose response vary with radiation quality and (2) they
have a rather limited lifetime. One of their main practicalities
lies in their small size allowing their insertion inside intra-
luminal catheters or even needles and the possibility of hav-
ing multiple MOSFET sensors along one single line. Recent
coupling of a MOSFET detector with a sensor capable of de-
tecting the position of the MOSFET in 3D (RADPOS), has
renewed interest in their use.
MOSFETs have been used to characterize the HDR 192Ir
Leipzig surface applicators and found to agree with films and
Monte Carlo calculations within 3%.79
Cygler et al.33 performed in 2006 a feasibility study using
micro-MOSFETS (external dimensions: 1 mm diameter by
0.5 mm thickness) during permanent low-dose rate prostate
implants as a tool for in vivo measurement of the initial dose
rate within the urethra and as a mean to help evaluate the over-
all quality of the implant. In this study, IVD in the urethra was
carried out by moving the MOSFET detector along the ure-
thra in 1 cm steps. The estimated uncertainty of the MOSFET
position was within ±1 mm. The detector was left at each po-
sition to accumulate dose for 10 min, long enough to provide
a reasonable measurement signal.
Bloemen-van Gurp et al.34, 80 performed two studies in
2009 using a linear MOSFET array during permanent prostate
implant. The overall uncertainty in the measurement proce-
dure, determined in a simulation experiment, was 8.0% and
an action level of ±16% (2 SD) for detection of errors in the
implantation procedure is achievable after validation of the
detector system and measurement conditions. In their second
study, they reported on a technique to monitor the dose rate in
the urethra and performed IVD in five patients during and af-
ter implantation of 125I seeds. They concluded that IVD with
MOSFET array during the procedure is a feasible technique
to evaluate the dose in the urethra for permanent prostate
BT. This study showed the challenges of performing IVD in
BT and the extensive analysis needed to reach a meaningful
conclusion.
Cherpak et al.81 performed real-time measurements of ure-
thral dose and position using a RADPOS Array (Best Medi-
cal Canada) during permanent seed implantation for prostate
BT. RADPOS Array is a modified RADPOS detector.82
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Cherpak et al.81 performed measurements on 17 patients and
concluded that the modified RADPOS detector with MOS-
FET array instead of a single MOSFET is able to provide ac-
curate real-time dose information which can be used to moni-
tor dose rates while implantation is performed and to estimate
total integrated dose. Reniers et al.83 in 2012, in a feasibility
study on a phantom, have studied the utility of using a RAD-
POS system for IVD for gynecological BT. They reported that
the RADPOS sensor, if placed, for example, in the bladder
Foley balloon, would detect a 2 mm motion of the bladder, at
a 5% chance of a false positive, with an action level limit of
9% of the dose delivered. The authors also found that source
position errors caused by, e.g., a wrong first dwell position,
are more difficult to detect. With a single RADPOS detector
positioned in the bladder, dwell position errors below 5 mm
and resulting in a dose error within 10% could be detected in
the tandem but not in the colpostats.
V.D. Alanine
L-α-alanine is a nonessential amino acid that has been
used for electron paramagnetic resonance (EPR) dosimetry
in radiation therapy. Alanine can exist in a form of a white
powder or can be formed in the shape of rods, pellets, films,
etc.84 During irradiation of alanine, permanent free radicals
are formed. The concentration of these radicals is proportional
to absorbed dose and can be measured by EPR spectroscopy.
So alanine is a chemical dosimeter, since dose measurement
is based on detection of chemical species formed during irra-
diation. Alanine has some important advantages as a dosime-
ter. Its response is almost independent of radiation energy and
dose rate. It can be formed into small shapes and requires no
bias or wiring. The readout of the radical concentration is non-
destructive and has very little fading with time.
Unfortunately, it also has disadvantages that limit its use-
fulness in clinical dosimetry. The main disadvantage is a re-
quirement of expensive EPR equipment not easily available
in clinics. Alanine does not provide an immediate readout of
the dose and it is generally insensitive to doses <2 Gy. It also
has some temperature and humidity dependence. In spite of
these limitations, some feasibility studies were conducted to
evaluate its usefulness in BT. Apart from the phantom stud-
ies aimed mostly at the characterization of the radioactive
sources,85–87 few reports exist on using alanine for IVD of
gynecological treatments.39, 88 Alanine is commercially avail-
able, but the tedious readout procedure needs to be established
individually in each department. At present, use of alanine in
the clinics is very limited due to the readout equipment being
very expensive and it is hard to foresee that this will change
in the near future.
V.E. RL and OSL detectors
Recent advances in optically stimulated luminescence
dosimeters (OSLDs) have opened new possibilities for their
application in radiation therapy.89, 90 OSLDs are gradually re-
placing TLDs as personal radiation monitoring dosimeters for
industry and public health workers because of their instanta-
neous reading capabilities, faster processing, and the ability
to store their reading without much degradation of the optical
signal (permanent record). To operate in the OSL mode, the
crystals need an external stimulation (laser or diode) to extract
the reading postirradiation. The same crystal can also operate
in the RL mode providing the information about the dose rate
during the irradiation, thus, serving as a true real-time online
detector. Al2O3:C can be formed as crystals with diameter
<1 mm which can fit inside BT catheters. Even though the
sensitive detecting material of these detectors (Al2O3:C) is
not water-equivalent, they have good potential for IVD in BT
due to their ability to provide feedback in real time.
RL systems for online dose measurements are not avail-
able. However, a prototype system developed by Andersen
et al.66 in 2009 was investigated to facilitate the prevention
and identification of dose delivery errors in remote afterload-
ing BT. The system consists of a small Al2O3:C crystal cou-
pled with the optical fiber which carries the light signal gen-
erated in the crystal to the detection system. The system is
capable to operate either in the RL or OSL mode. The sys-
tem allows for automatic online IVD directly in the tumor re-
gion using small detector probes that fit into applicators such
as standard needles or catheters. In the RL mode, the sys-
tem is capable of measuring the absorbed dose rate (with a
0.1 s time resolution) and in the OSL mode—the total ab-
sorbed dose. The calibrated system was found to be linear
in the tested dose range. The reproducibility for the RL/OSL
measurements was found to be 1.3% (SD). Under certain con-
ditions, the RL signal could be greatly disturbed by the so-
called stem signal (i.e., unwanted light generated in the fiber
cable upon irradiation).91 When taking into account the ef-
fect of reproducibility, energy response, angular dependence,
stem effect, instrument and crystal temperature, light guide
transmission on the reading, and the calibration uncertainty,
the combined estimated uncertainty budget was found to be
8% (SD) and 5% (SD) for RL and OSL, respectively. This
initial study was followed up with a clinical protocol study on
five cervix cancer patients undergoing PDR BT.35 For three
of the patients, the authors found no significant differences
(p > 0.01) between IVD and TPS calculated reference values
(TG 43) at the level of dose per dwell position, dose per appli-
cator, or total dose per pulse. For the two other patients, they
noted significant deviations for three individual pulses and for
one dosimeter probe. These differences could have been due
to applicator movement during the treatment and/or an incor-
rectly positioned probe, respectively.
Kertzscher et al.36 in 2011 tested the ability of a RL sys-
tem to identify afterloading PDR and HDR gynecological and
prostate BT errors in real time using a novel statistical er-
ror decision criterion. Their phantom studies showed that out
of 20 interchanged guide tube errors, time-resolved analysis
identified 17 while accumulated dose identified only two. Ac-
cumulated dose comparisons could leave 10 mm dosimeter
displacement errors unidentified and while dose rate compar-
isons correctly identified displacements ≥5 mm. This phan-
tom study demonstrated that Al2O3:C real-time dosimetry has
the potential to detect interchanged guide tube errors during
PDR and HDR BT and has the ability to identify applicator
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displacements ≥5 mm. Another important aspect of this study
was to highlight the shortcoming of using a constant error cri-
terion and instead to recommend using a statistical error cri-
terion.
V.F. Plastic scintillation detectors
Plastic scintillation detectors are a promising option for
IVD. PSDs are composed of organic scintillation material
(scintillator or scintillating optical fiber) that emits light pro-
portionally to the dose deposited in their detector volume. The
light produced in the detector is usually optically coupled to
a fiber-optic light guide and transmitted toward a photodetec-
tor. The properties of plastic scintillation detectors have been
studied for high-energy external beams.67, 92 High spatial res-
olution, linearity with dose, energy independence in the mega-
voltage energy range, and water equivalence are among the
advantages that have been demonstrated for such detectors.
Cerenkov light production has also been identified in the op-
tical guide.67, 92, 93 This light component, often referred to as
stem effect, is produced in the fiber when struck by radiation
over a certain energy threshold, which depends on fiber mate-
rial, and needs to be removed to perform accurate dosimetry.
Different methods have been proposed to efficiently account
for this spurious effect.94, 95 Using these detectors, possibil-
ity of real-time IVD has been demonstrated under external
beam radiation96 and accuracy of better than 1% has been
achieved. New evidence pointing to possible temperature de-
pendence has recently been reported as a characteristic being
exhibited by plastic scintillation detectors.97 An average of a
0.6% decrease in measured dose/◦C relative to dose measured
at room temperature was observed in the range of 15–50 ◦C.
At the present time, it is not clear if this thermal dependence
comes from the construction of the materials used in the de-
sign, the composition of the organic scintillator itself, or is
coming from the optical train. Since the exact mechanism is
not well understood, this early communication concluded that
further research is warranted.
PSDs have the capability to perform accurate online IVD
during HDR 192Ir BT,58, 68, 69 because they could be cut and
shaped in size that can be easily inserted into catheters or
arranged around applicators that are commonly used in BT.
Lambert et al.58 performed a comparative phantom study of
PSDs to other commercially available detectors (MOSFET,
diamond detector, and TLD). Based on size, accuracy, and
real-time possibilities, the authors claimed that PSDs showed
the best combination of characteristics to perform dosimetry
during HDR 192Ir BT. Because the energy emission spectrum
of an 192Ir radiation source is mainly higher than the Cerenkov
production threshold energy, the need for a stem removal tech-
nique has been stressed for clinically relevant situations.68 A
study using a prostate phantom was performed by Therriault-
Proulx et al.69 The authors used a red–green–blue (RGB) pho-
todiode as the photodetection component, allowing for the re-
moval of the Cerenkov component through the polychromatic
approach. Thirteen catheters were implanted in the phantom:
12 for dose delivery and one for the PSD. The PSD dose rates
were measured in real-time during the treatment delivery us-
ing a HDR 192Ir source. The average accumulated dose mea-
sured at the PSD location for five consecutive treatment deliv-
eries was 275 ± 14 cGy, in good agreement with the expected
dose of 275 cGy as calculated by the treatment planning sys-
tem. Another phantom study using an array of 16 PSDs in
an insertable applicator that enables quality assurance of the
treatment delivery and provides an alert to potential radiation
accidents during HDR BT treatments has been performed by
Cartwright et al.70 The system presented is capable of measur-
ing doses in a phantom for 1 s exposures with an uncertainty
between 2% and 3% for most of the PSDs.
Suchowerska et al.41 described a plastic scintillator system
consisting of a 0.5 mm diameter by 4 mm length BC400 scin-
tillator optically coupled to a 0.48 mm core PMMA optical
fiber to transmit the signal. They have used a PTW-Freiburg
OPTIDOS Reader to read the signal produced by their scin-
tillator detector.41 The OPTIDOS reader, consisting of a pho-
tomultiplier and an electrometer unit, was originally designed
to measure the dose rate of 90Sr/90Y beta emitting sources as
well as for 32P intravascular BT using different plastic scintil-
lator detectors designed and manufactured by PTW-Freiburg.
Note that the PTW-Freiburg scintillation detectors and OPTI-
DOS reader system are no longer commercially available. The
clinical feasibility of this study examined urethral dose mea-
surements in 24 patients during HDR prostate BT. The authors
of this study did not report any temperature dependence for
their measurement performed inside the urethra nor any stem
effect when using these PSDs. After the first 14 patients, im-
provements to the dosimeter system design were implemented
that increased positional accuracy and system reliability, with
the maximum dose departure from the calculated dose being
within 9% for all of the ten remaining patients and concluded
that dose to the urethra could be accurately measured using
the improved system.
At the present time there are no PSDs or PSD systems
that are commercially available for use for in vivo dosime-
try for BT. The only PSD system available commercially is
the EXRADIN W1 Scintillator manufactured by Standard
Imaging which was designed for external beam radiother-
apy and more specifically for the characterization of small
field dosimetry (http://www.standardimaging.com/product_
home.php?id=124).
VI. DIRECTIONS FOR THE FUTURE
VI.A. Detectors and technology
Most of the development efforts for IVD systems have
been focused to the front end of the detection system: the de-
tector element(s) or the sensitive material and their dosimetric
characteristics to correct for the effects influencing their re-
sponse. Future developments would have to be focused on the
back end of the detection system utilized to process the data
(i.e., the readings of the detector) to make the next generation
“IVD systems” user friendly with automatic data display, re-
quiring less manpower, with no postdata analysis or special
expertise needed. Furthermore, in order to be successful for
widespread use, any new technological innovation for such
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systems will have to be well integrated into the routine clini-
cal application being targeted.
Given existing alternatives for accurate BT dosimeters, fu-
ture requirements will likely be made on IVD systems that can
monitor the dose in real time, are sensitive to displacements
of all applicators involved in the treatment, can identify organ
motion, and that can provide immediate alerts of any potential
gross error during ongoing treatments. Passive detectors, such
as TLDs, OSLDs (when used in the passive mode), RPLDs,
alanine, radiographic and radiochromic films, gels, are not ca-
pable of monitoring the time-resolved treatment delivery. A
few studies have introduced the possibility of using the instan-
taneous dose rate for patient QC checks.31, 35, 36 These stud-
ies indicate that time-resolved dosimetry has potential to be
more sensitive to error detection than dose verification based
on integral dose. Therefore, future research will probably fo-
cus on further developing systems that would have the abil-
ity to sample the dose rate in real time while the radiation
treatment is being delivered to the patient. Currently, good
candidates for real-time IVD are RL,35, 36 PSDs,69 and MOS-
FETs. These detectors are capable of sampling or measuring
the dose rate which could be useful for certain applications
for which thresholds in dose deviations could be set and/or
upper and lower limits for dose values to prevent gross errors
and potentially alert the users whether the treatment should
or should not be terminated. Although semiconductor diodes
provide an immediate readout, they are not good candidates
for real-time IVD due to their many undesirable dosimetric
characteristics (see Table I).
Recently, it has been shown that it is possible to develop
detectors composed of multiple different color PSDs (mPSD)
using a single optical transmission line and capable of mea-
suring the dose accurately (Fig. 2).98 Detectors of this type
could be used for LDR or HDR interstitial BT applications.
Additional “carrier catheters” could be sutured within the
vicinity of the implant or nearby a critical structure to monitor
the dose from the planned implant. The “carrier catheters” are
not part of the implant but additional intraluminal catheters
for the sole purpose to accommodate the detectors. The read-
ings consist of the light spectrum emitted by each color PSD.
The extraction of each corresponding color from the total
spectrum measured will provide the dose deposited at corre-
sponding color PSD. This type of detector has the advantage
of simultaneous dose rate measurements in multiple points
with the potential to improve error detection capabilities.
FIG. 2. mPSD line detector inserted into a flexible catheter.
FIG. 3. An example of integrating a detector to a rectal balloon. In this case,
a 0.5 mm diameter by 1.0 mm long plastic scintillating fiber coupled to a
clear transmitting fiber-optic and an inflatable rectal balloon (upper left) were
fully integrated into an inflatable rectal balloon with the detector permanently
moulded to it (upper right). Another example illustrating integrating a com-
bination of line detectors and point detectors integrated to an applicator is
shown below. A semicylindrical cut of the rectal balloon surface onto which,
in this case scintillating line and point probes are attached for detection of
dose along the rectal wall. The individual line and point probes slide into
capillary tubes permanently attached to the balloon surface.
Stable and clinically relevant detector positioning remains
one of the most important and critical issues for IVD. Inser-
tion of additional detector catheters may be performed with
the purpose of optimizing detector positioning, e.g., by in-
serting an additional interstitial needle for housing a dosime-
ter probe in the tumor region. A smaller invasive impact may
be achieved by inserting a sterilized dosimeter in the urethral
catheter for urethral dose measurements. However, such in-
vasive procedures raise ethical issues as discussed in Sec.
IV.A. Another option is to mould detectors within an appli-
cator (see example in Fig. 3), which has advantages such as
fixing the sensitive volume within the geometry of the appli-
cator and therefore reducing the positional uncertainty of the
detector. The applicator could potentially be designed to con-
strain movements of OARs and/or the target region. Similar
measures could be achieved with a urethral catheter with a
closed-end lumen dedicated for housing a dosimeter probe in
the urethra or along the bladder wall.
Improved integration between afterloader and dosimetry
system is warranted. The Bebig Multisource afterloader (by
Eckert & Ziegler Bebig GmbH, Berlin, Germany) offers in-
tegrated diode IVD where the dosimetry system can be op-
erated from the control unit. It permits the specification of
dose limits and the display of rectum and bladder doses.
A further step forward for integration would be automated
DICOM import to the dosimeter software and signal commu-
nication between the dosimeter software and the afterloader.
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The communication would help synchronize the dosimeter
readout with the onset of the treatment, hence, optimize the
comparison between the delivered treatment with the time and
source coordinates from the imported DICOM RT plan. An-
other attractive solution for future IVD in BT is the integra-
tion of one or several dosimeter probes into the afterloading
machinery. Such an afterloader could offer motorized feeding
of dosimeter probes into BT catheters already inserted into
the patient but unoccupied by the source. Positioning technol-
ogy attached onto both the source wire and dosimeter probe
could both minimize their positional uncertainties and opti-
mize the relative source-to-dosimeter distances. In vivo de-
tector positioning directly inside the source catheters, e.g.,
needles and intracavitary tubes, would in principle already
be possible with sufficiently small dosimeter probes as the
RADPOS, MOSFETs and fiber-coupled scintillator, and RL
probes.
Recently developed RADPOS system82, 99, 100 allows for si-
multaneous measurement of dose and position. This detector
is particularly suited for BT applications and is being explored
to study not only its sensitivity for error detection during HDR
treatments81 but also for applicator movement during vaginal
cylinder treatments and prostate movement during permanent
prostate implants.81 RADPOS is capable of detecting prostate
movement during each needle insertion, as well as the change
in the urethral dose after the removal of the ultrasound probe
from the rectum.81 Since the RADPOS probe is visible on x-
ray images, it allows to link the coordinates of the point of
measurement before and during the treatment.
VI.B. Error detection criteria
A significant challenge of future IVD is to define relevant
error/decision criteria which take into account that both sen-
sitivity and specificity of treatment error detection is sound
and robust in a clinical setting. More advanced error deci-
sion criteria could involve a statistical approach where the
comparison between calculated and measured doses takes
into account the uncertainty components for both calculated
and measured doses. The calculated dose is based on assess-
ment of both source and detector positions as they are iden-
tified, e.g., in 3D images (US, CT, or MRI) during treat-
ment planning. The identification of both source and detector
position is correlated with specific reconstruction uncertain-
ties. The influence of positional uncertainties on the calcu-
lated dose may be quantified by simulation which incorpo-
rates the source/detector geometry as known from the TPS
and an assumption of a certain distribution of positioning
errors.35, 36 Furthermore, dose calculation is correlated with
uncertainties due to the shortcomings of dose calculation al-
gorithms imposed, e.g., by inhomogeneities and scatter con-
ditions. The uncertainty on the measured dose has a number
of components which are related to the detector characteris-
tics. Based on comparison between calculated and measured
doses, the measurement should be categorized into “Alarm”
or “No alarm.” A certain action level should be defined by
balancing between sensitivity and false alarms (Table II). The
action level can be based on a statistical evaluation of the
incidence of a type 1 error (false alarm), e.g., p = 0.05 or
p = 0.01 which means that 5% or 1% of all correct treatments
will induce a false alarm, respectively.
The accuracy of the “Alarm classification” depends on the
magnitude of components in the entire uncertainty budget and
as such can be optimized by reducing uncertainties. These fac-
tors relate to the dosimeter technology, e.g., calibration accu-
racy and energy dependence, and to clinical procedures, e.g.,
image reconstruction and patient-DICOM matching. An op-
timized dosimetry integration into the entire BT workflow
would reduce the incidence of false alarms (type I errors)
and/or decrease the failure to detect treatment errors (type
II errors). This would improve treatment error detection and
minimize the risk of making erroneous decisions regarding
unnecessary treatment interruptions or termination.
An interesting strategy for further improvement of error
decision criteria could be development of a gamma analysis
for IVD according to the principles which have been used
in EBRT for comparison of measured and expected doses,
e.g., with EPID dosimetry.101 With a gamma analysis an er-
ror criterion would be based not only on a dose difference but
could also combine it with a distance-to-agreement criterion.
In such an analysis, the upfront knowledge of the geometri-
cal uncertainties of the detector and source positioning could
be incorporated into the model in order to decide on relevant
distance-to-agreement criteria.
VI.C. Clinical operation, infrastructure, and workflow
Patient involvement should be considered so that the pa-
tient is as comfortable as possible and not stressed by ad-
ditional procedures if possible. Current rectal diode systems
and/or additional catheter insertion into the urethra/bladder
involve some patient discomfort. Reduction of detector size
may contribute to improved patient acceptance. Optimally,
the use of BT source catheters for in vivo detectors, as dis-
cussed in Sec. VI.A, would not require any extra insertion of
catheters, and could potentially make the in vivo system com-
pletely “invisible” for the patient.
A major barrier for routine implementation of IVD is the
added workload for the personnel. Developments of new sys-
tems should involve considerations of time consumption, clin-
ical robustness, and ease of use. The Quality Management
Program should be optimized in order to limit the time con-
sumption for the personnel. The measurements should be pre-
sented and visualized to the user in such a way that the evalu-
ation and interpretation of the results is as straightforward as
possible and so that a clear action can be taken from the mea-
surements. The IVD system should also not distract personnel
from other important tasks related to treatment planning and
dose delivery.
An example of a general dosimetry integration into an im-
age guided BT workflow is shown in the right pane of Fig. 4.
Some potential sources of errors generated during such treat-
ment procedures are specified in the left pane, where those
detectable with IVD are highlighted.
An optimal dosimetry integration would involve source
applicators with integrated dosimeter housing, which would
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FIG. 4. Example of workflow for CT/MR image guided BT. Potential discrepancies between planned and delivered treatments may originate from errors (see
left pane) presented at different stages of the treatment workflow (see right pane). In principle, in vivo dosimetry addresses detection of the highlighted error
types.
not require additional work for the physician during the im-
plantation stage in the operation theatre. As discussed in
Sec. VI.A, the dosimeter housing could provide anatomical
stability in order to minimize the impact of the patient trans-
fer stages on the original positions of the source and dosime-
ter catheters. Furthermore, contrast material could be more
systematically incorporated into the catheters in order to aid
accurate reconstruction of the dosimeter and source dwell po-
sitions from CT/MR images. MRI imposes significant chal-
lenges since traditional metal markers do not induce contrast
on MRI, hence, alternative fluid markers may be used for in-
dication of reference points or source/dosimeter catheters. In
addition to control checks by the staff, connection errors be-
tween the afterloader and the dosimeter, and their designated
catheters, could be reduced, e.g., by using different connec-
tion mechanisms for the dosimeter and source catheters.
Improvements of sterilization options would also have po-
tential to improve the clinical workflow. National or hospi-
tal requirements do not always match with company require-
ments, and may prevent the use of IVD. Therefore, larger
flexibility of sterilization methods is needed for overall appli-
cation of the IVD techniques. Introduction of single use sterile
sheaths for the dosimeter probes may be a practical approach
in certain clinical scenarios.
VI.D. Specific key questions for future in vivo
dosimetry
There is significant potential for IVD to move forward into
a new era of increased sensitivity and specificity for error de-
tection. However, a number of essential issues need to be ad-
dressed as discussed above. The following is a list of impor-
tant questions when considering new routes or approaches:
 Detector selection: Is the detector favorable for BT in
terms of its characteristics, size, and sensitivity?
 Operation of in vivo system: Is the system practi-
cal in terms of calibration, quality management proce-
dures, stability, robustness, size of the system, ease of
operation?
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 Infrastructure: Is online dosimetry exploited? Is auto-
matic analysis of data incorporated?
 Detector position: Is the positional accuracy of the de-
tector addressed and optimized?
 Error decision criteria: Fixed level or statistical ap-
proach?
 Sensitivity and specificity: Is the sensitivity and speci-
ficity of the system evaluated?
 Communication: Is the dosimetry system able to com-
municate with TPS and/or afterloader?
 Prospective IVD: Is IVD used prospectively and system-
atically to evaluate the incidence of errors?
Recent progress of IVD shows that some of these points
have already been addressed individually in different publi-
cations. However, the aim and vision for IVD is to create a
system that embraces all the above aspects.
VII. CONCLUSIONS
The specific role of IVD in BT needs to be defined and es-
tablished. So far, recommendations for BT practice rarely in-
clude the recommendation to perform IVD. This fact is most
likely mainly influenced by the poor ability of current sys-
tems to detect errors. Nevertheless, IVD is used in several de-
partments and there is good potential to improve its utility
and use. Most importantly, incorporation of routine IVD into
clinical practice requires that the error detection capability is
improved. Second, streamlined procedures are needed which
are automatic as far as possible so that the work load is not
excessive and so that the medical physicist is not distracted
by technical operation. The systems need to be commercially
available and affordable. Further utilization and dissemina-
tion of IVD will only be feasible if it is cost effective to as-
sign resources for its infrastructure. Altogether, it should be
demonstrated that IVD can be developed to become sensitive
to errors that may have clinical impact and avoidance of errors
should be verified.
Proceeding from this, it is crucial to come to a compre-
hensive description of errors in order to make progress within
BT safety. Systematic IVD in a multicenter setting would be a
step forward for detecting and understanding errors and their
frequencies. Support of international databases for error re-
porting and for logging user experiences is important, since
publications from academic centers do not reflect the major-
ity of patient treatments. The Radiation Oncology Safety In-
formation System (ROSIS) database supported by ESTRO al-
ready supports reporting of BT incidents and the first reports
from ROSIS include such incidents.102 Such practice has po-
tential to facilitate significant improvements in quality for BT
by (1) advancing the use of IVD systems in order to prevent
and avoid BT errors and (2) making it possible to focus on the
most relevant sources of errors.
It is the opinion of the authors that IVD in BT is currently
not well established in clinical routine to be used for sensitive
and specific error detection. However, this situation should
change over the coming years by investing in development of
IVD with the goal of establishing an efficient means of inde-
pendent verification of dose delivery in BT. As soon as IVD in
BT becomes better established, there will be a strong need for
recommendations from professional organizations (e.g., ES-
TRO, ASTRO, AAPM, ABS).
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